Equities analysts forecast that United Therapeutics Co. (NASDAQ:UTHR) will announce sales of $349.25 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for United Therapeutics’ earnings. The highest sales estimate is $412.13 million and the lowest is $310.00 million. United Therapeutics reported sales of $444.60 million during the same quarter last year, which suggests a negative year over year growth rate of 21.4%. The company is expected to announce its next earnings results on Thursday, July 26th.

According to Zacks, analysts expect that United Therapeutics will report full year sales of $1.38 billion for the current fiscal year, with estimates ranging from $1.34 billion to $1.42 billion. For the next fiscal year, analysts forecast that the business will report sales of $1.21 billion per share, with estimates ranging from $1.11 billion to $1.38 billion. Zacks’ sales calculations are an average based on a survey of research analysts that cover United Therapeutics.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 2nd. The biotechnology company reported $5.57 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.62 by $1.95. The company had revenue of $389.20 million during the quarter, compared to the consensus estimate of $393.96 million. United Therapeutics had a return on equity of 26.68% and a net margin of 27.74%. United Therapeutics’s revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the firm posted $3.61 EPS.

Several analysts have recently issued reports on UTHR shares. ValuEngine cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 2nd. Credit Suisse Group lowered their price objective on shares of United Therapeutics from $108.00 to $104.00 and set a “neutral” rating for the company in a research note on Thursday, May 3rd. BidaskClub raised shares of United Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 16th. Finally, Barclays lowered their price objective on shares of United Therapeutics from $105.00 to $95.00 and set an “underweight” rating for the company in a research note on Thursday, May 3rd. Four research analysts have rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company’s stock. United Therapeutics has an average rating of “Hold” and a consensus price target of $134.00.

Shares of United Therapeutics opened at $106.58 on Friday, according to MarketBeat Ratings. United Therapeutics has a fifty-two week low of $100.57 and a fifty-two week high of $152.55. The firm has a market capitalization of $4.58 billion, a price-to-earnings ratio of 9.79, a price-to-earnings-growth ratio of 26.91 and a beta of 1.33. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.13 and a quick ratio of 4.81.

In related news, CEO Martine A. Rothblatt sold 43,025 shares of the company’s stock in a transaction on Friday, March 16th. The shares were sold at an average price of $111.11, for a total transaction of $4,780,507.75. Following the completion of the sale, the chief executive officer now directly owns 21,652 shares of the company’s stock, valued at approximately $2,405,753.72. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 301 shares of the company’s stock in a transaction on Tuesday, March 20th. The stock was sold at an average price of $110.48, for a total transaction of $33,254.48. Following the sale, the chief executive officer now directly owns 21,652 shares of the company’s stock, valued at $2,392,112.96. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 174,046 shares of company stock valued at $19,506,251. 8.20% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in UTHR. Wedge Capital Management L L P NC boosted its position in United Therapeutics by 2,725.8% during the 4th quarter. Wedge Capital Management L L P NC now owns 324,631 shares of the biotechnology company’s stock worth $48,029,000 after purchasing an additional 313,143 shares during the period. Renaissance Technologies LLC boosted its position in United Therapeutics by 14.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,462,378 shares of the biotechnology company’s stock valued at $216,359,000 after buying an additional 189,378 shares during the last quarter. LSV Asset Management boosted its position in United Therapeutics by 53.3% in the 1st quarter. LSV Asset Management now owns 420,340 shares of the biotechnology company’s stock valued at $47,229,000 after buying an additional 146,194 shares during the last quarter. BlackRock Inc. boosted its position in United Therapeutics by 3.0% in the 1st quarter. BlackRock Inc. now owns 4,912,985 shares of the biotechnology company’s stock valued at $552,023,000 after buying an additional 141,416 shares during the last quarter. Finally, Mackay Shields LLC purchased a new position in United Therapeutics in the 1st quarter valued at about $14,199,000. 99.18% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Get a free copy of the Zacks research report on United Therapeutics (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.